key: cord-0265122-lz2hpjjw
authors: Chen, Z.; Zhang, P.; Matsuoka, Y.; Tsybovsky, Y.; West, K.; Santos, C.; Boyd, L. F.; Nguyen, H.; Pomerenke, A.; Stephens, T.; Olia, A. S.; De Giorgi, V.; Holbrook, M. R.; Gross, R.; Postnikova, E.; Garza, N. L.; Johnson, R. F.; Margulies, D. H.; Kwong, P. D.; Alter, H. J.; Buchholz, U. J.; Lusso, P.; Farci, P.
title: Extremely potent monoclonal antibodies neutralize Omicron and other SARS-CoV-2 variants
date: 2022-01-13
journal: nan
DOI: 10.1101/2022.01.12.22269023
sha: 8c453c0209e47fb451763b106b6a820662275c44
doc_id: 265122
cord_uid: lz2hpjjw

The ongoing coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has triggered a devastating global health, social and economic crisis. The RNA nature and broad circulation of this virus facilitate the accumulation of mutations, leading to the continuous emergence of variants of concern with increased transmissibility or pathogenicity1. This poses a major challenge to the effectiveness of current vaccines and therapeutic antibodies1,2. Thus, there is an urgent need for effective therapeutic and preventive measures with a broad spectrum of action, especially against variants with an unparalleled number of mutations such as the recently emerged Omicron variant, which is rapidly spreading across the globe3. Here, we used combinatorial antibody phage-display libraries from convalescent COVID-19 patients to generate monoclonal antibodies against the receptor-binding domain of the SARS-CoV-2 spike protein with ultrapotent neutralizing activity. One such antibody, NE12, neutralizes an early isolate, the WA-1 strain, as well as the Alpha and Delta variants with half-maximal inhibitory concentrations at picomolar level. A second antibody, NA8, has an unusual breadth of neutralization, with picomolar activity against both the Beta and Omicron variants. The prophylactic and therapeutic efficacy of NE12 and NA8 was confirmed in preclinical studies in the golden Syrian hamster model. Analysis by cryo-EM illustrated the structural basis for the neutralization properties of NE12 and NA8. Potent and broadly neutralizing antibodies against conserved regions of the SARS-CoV-2 spike protein may play a key role against future variants of concern that evade immune control.

cross-competition with the exception of two, 1G8 and 3F6, which cross-competed only between each other (Extended Data Fig. 5 ).

Next, using a pseudotype virus assay, we tested our mAbs against different VOCs of global relevance, namely, B.1.1.7/Alpha, B.1.351/Beta, B.1.617.2/Delta and B.1.1.529/Omicron, and compared their efficacy with that of three antibodies approved for clinical use, Lilly_CoV555 (Bamlanivimab) 28 , REGN10933 Casirivimab) and REGN10987 (Imdevimab) 29, 30 ( Fig. 1h) . We found 7 mAbs that potently neutralized the WA-1 strain, the B. Fig. 1h) , whereas none of the clinically approved antibodies we tested showed neutralizing activity. Three additional mAbs (2A12, 3F6 and NE12) neutralized the Omicron variant, albeit in the nanomolar range (Fig. 1h) . The neutralizing activity of our mAbs was also tested using a live virus neutralization assay against the original strain, WA-1, and the B.1.351/Beta variant (Fig.   1i ). Even though this assay was less sensitive than the pseudovirus assay, the neutralization profile was similar overall, as shown by a strong correlation between the results obtained in the two assays (Fig. 1j) . Importantly, our best mAbs were more potent than the clinically approved mAb Lilly_CoV555 against WA-1, with IC50 values more than 4-fold lower; furthermore, NA8 potently neutralized the B1.351 variant while the Lilly_CoV555 mAb had no activity (Fig. 1i) .

Based on the in vitro neutralization data, two mAbs, NE12 and NA8, were selected for further characterization and development. Complete neutralization curves for these two mAbs are shown in Fig.1k ,l.

for use under a CC0 license. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 13, 2022. ; https://doi.org/10.1101/2022.01.12.22269023 doi: medRxiv preprint Next, we tested the in vivo prophylactic efficacy of mAbs NE12 and NA8 in the golden Syrian hamster model, which closely mimics the severity of the disease in humans 31, 32 . A total of 80 male hamsters were used for these experiments; each of the study groups included 10 hamsters.

The animals were inoculated with mAbs at two concentrations (12 and 4 mg/kg) via intraperitoneal (IP) injection 24 h before challenge with 4.5 log10 TCID50 of SARS-CoV-2 WA-1 or B.1.351/Beta by intranasal (IN) instillation (Fig. 2a ). An isotype-matched (IgG1) irrelevant mAb, the anti-HIV-1 VRC01, was included as a control at 12 mg/kg. Based on the in vitro neutralization results, both NA8 and NE12 were tested against the WA-1 strain (Fig.2b,d,e) , while only NA8 was tested against the B.1.351/Beta variant (Fig.2c ,f,g). Animals treated with the control IgG1 lost, on average, 9% and 8% of body weight by day 5 after challenge with WA-1 and B.1.351, respectively (Fig. 2b,c) . In contrast, treatment with NE12 or NA8 significantly protected hamsters from weight loss induced by the two viral variants, although NA8 at 4 mg/kg against the B.1.351 virus showed a lesser degree of protection (Fig. 2c) . The protective effect of NE12 and NA8 was confirmed by viral load measurements in nasal turbinate and lung tissues on days 3 and 5 after inoculation (n=5 per time point per group). In animals treated with NE12 or NA8 at either 12 or 4 mg/kg, the viral titers at day 3 post-infection with the WA-1 virus were significantly reduced in both tissues compared to controls; in the lungs, the virus became undetectable at day 5 post-infection (Fig.2d,e) . Likewise, in animals infected with the B.1.351 variant, NA8 at both concentrations significantly reduced the viral titers in nasal turbinate and lung tissues at day 3 post-infection and completely suppressed viral replication in the lungs at day 5 ( Fig.2 f,g) . Overall, these data demonstrate that mAb NA8 exerted strong prophylactic protection in vivo from two antigenically distinct SARS-CoV-2 variants, and NE12 exerted strong prophylactic protection against SARS-CoV-2 WA-1 in a highly susceptible animal model, despite the relatively low antibody doses used.

for use under a CC0 license. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 13, 2022. ; https://doi.org/10.1101/2022.01.12.22269023 doi: medRxiv preprint A total of 60 golden Syrian hamsters, divided in 6 groups of 10 animals each, were utilized for a therapeutic study. Three groups of animals were infected intranasally with the original strain, WA-1, and 3 groups with the B.1.351 variant (4.5 log10 TCID50 per animal). The therapeutic efficacy of mAb NE12 or NA8 (each at 12 mg/kg) was evaluated by administering the antibodies via the IP route 24 hours after IN instillation, which is a very stringent model given the extremely rapid kinetics of replication of SARS-CoV-2 (Fig. 3a) . The IgG1 isotype control mAb VRC01 (12 mg/kg) was tested in parallel as a control. Five hamsters per group were sacrificed at day 3 post-infection for tissue viral load measurements, while the remaining 5 animals were weighed daily until day 11. No significant differences in weight loss were observed among the three groups of hamsters infected with WA-1 (Fig. 3b ). In contrast, NA8 significantly reduced the weight loss caused by infection with the B.1.351/Beta variant, which remained below 5% of the initial body weight throughout the observation period in contrast with the marked loss (nearly 15%) seen in the control group (Fig. 3c) . Analysis of viral titers in nasal turbinate and lung tissues showed a significant reduction in both NE12-and NA8-treated animals infected with WA-1, despite a wide data distribution in animals treated with NE12 (Fig. 3d,e) . The serum concentrations of NA8 and NE12 were measured on day 3 after infection. In the NE12/WA-1 group, the antibody titers varied greatly; high viral titers in nasal turbinates and lungs strongly correlated with low to undetectable antibody levels in serum of three animals (Extended Data Fig. 6a,b) . In hamsters infected with B.1.351, treatment with NA8 induced a significant reduction in viral titers in both nasal turbinate and lung tissues while, as expected, NE12 was ineffective (Fig. 3f,g) . Altogether, these results demonstrate that both NE12 and NA8 exerted strong therapeutic effects against sensitive SARS-CoV-2 strains in a suitable preclinical model.

Cryo-EM analysis was used to determine the structures of Fabs NE12 and NA8 in complex with a stabilized SARS-CoV-2 spike protein trimer (S-6P) at nominal resolutions of 3.1 Å and 2.9 Å, respectively 33 (Fig. 4a ,d, Extended Data Table 4 , Extended Data Fig. 7-10) . The Fab-RBD for use under a CC0 license. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 13, 2022. ; https://doi.org/10.1101/2022.01.12.22269023 doi: medRxiv preprint interfaces were resolved using local refinement to 3.4 Å (NE12 complex) and 3.5 Å (NA8 complex) (Fig. 4b ,e, Extended Data Fig.11 ,12. Fab NE12 interacts with the face of the receptorbinding ridge of the RBD in both the up and down positions (Fig. 4a) . The interaction buries 874 Å 2 of the Fab surface area, split nearly equally between the heavy (465 Å 2 ) and light (409 Å 2 ) chains. The 17 residue-long complementarity-determining region (CDR) 3 of the heavy chain (CDRH3) and the CDR1 of the light chain (CDRL1) straddle the receptor-binding ridge, while the CDRL3 and CDRH2 interact with the tip of the RBD (Fig. 4c) . The CDRH1 is disordered, while the CDRL2 interacts with the region of the receptor-binding ridge distant from the tip. The epitope of this Barnes class-2 antibody 34 overlaps with those of mAbs Lilly_CoV555 28 and REGN10933 29 , as well as with the ACE2 receptor footprint 35 , indicating that NE12 directly blocks the spike-receptor interaction (Extended Data Fig.13 ). This mechanism was confirmed by binding competition studies on ACE2-expressing cells (Extended Data Fig. 14) . Residues mutated in the B.1.1.7/Alpha and B.1.617.2/Delta variants are located outside or at the periphery of the NE12 epitope, thus allowing for a potent neutralization of these variants (Fig. 4g) . In contrast, the E484K mutation of B.1.351 results in clashes with CDRH2 and CDRL3 residues, compromising the neutralizing activity. Likewise, multiple replacements in the B.1.1.529/Omicron RBD receptor-binding ridge can prevent NE12-spike interactions (Fig. 4i ).

The structure of Fab NA8 also shows extensive contacts with the receptor-binding ridge, but this antibody binds along the outer side of the RBD distal from the tip (Fig. 4e ,f), displaying characteristics of both class-2 and class-3 antibodies 34 . Binding competition studies on ACE2expressing cells showed evidence that NA8 reduced the interaction between the spike trimer and ACE2 by 90% (Extended Data Fig. 14) . The interaction buries 981 Å 2 of the Fab surface area, with the heavy chain responsible for most contacts (642 Å 2 ). The CDRH3 forms a long loop positioned along the side of the RBD, whereas the CDRH1 and CDRH2 contact the central region of the receptor-binding ridge. The CDRL1 and CDRL2 interact with the side of the RBD, while the CDRL3 contacts the loop formed by RBD residues 444-447. Of the residues mutated in the included VOCs, only L452 is part of the NA8 epitope (Fig. 4h) , which can explain the reduced neutralization of B.1.617.2/Delta (Fig. 2h) . Noteworthy, all the B.1.351/Beta and for use under a CC0 license. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Fig.15,16) , which is consistent with the high neutralization potency of NA8 against these VOCs.

In this study, we report the generation by combinatorial phage-display library technology of 11 10, 36, 37 , albeit with markedly lower neutralization potency compared to NA8. Considering the reduced efficacy of current vaccines and the complete loss or reduced neutralizing activity by most clinically approved antibodies [10] [11] [12] [13] [14] [15] 36, 37 , the identification of new antibodies capable of blocking not only the Beta but also the Omicron variant is important for future therapeutic and preventive strategies. Corroborating the potential clinical usefulness of our antibodies, the in vitro neutralization potency of NE12 and NA8 was confirmed in a hamster model in vivo, with for use under a CC0 license. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Structural analysis revealed different modes of binding of NE12 and NA8 to the SARS-CoV-2 spike. Like other class-2 antibodies, which neutralize the virus by blocking the spike interaction with the ACE2 receptor, NE12 binds to the receptor-binding ridge of the RBD. In line with a similar neutralization profile, there is a substantial overlap between the NE12 epitope and that of clinically approved mAb Lilly_CoV555. In contrast, the highly conserved NA8 epitope includes a portion of the receptor-binding ridge but is shifted toward the outer side of the RBD, allowing the antibody to "sidestep" the residues that are mutated in B. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 13, 2022. ; https://doi.org/10.1101/2022.01.12.22269023 doi: medRxiv preprint This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 13, 2022. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 13, 2022. ; This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 13, 2022. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 13, 2022. ; https://doi.org/10.1101/2022.01.12.22269023 doi: medRxiv preprint This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 13, 2022. ;

for use under a CC0 license.

This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 13, 2022. ; https://doi.org/10.1101/2022.01.12.22269023 doi: medRxiv preprint This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. for use under a CC0 license.

This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 13, 2022. for use under a CC0 license.

This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 13, 2022. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 13, 2022. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 13, 2022. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 13, 2022. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 13, 2022. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 13, 2022. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 13, 2022. ; https://doi.org/10.1101/2022.01.12.22269023 doi: medRxiv preprint This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 13, 2022. ; https://doi.org/10.1101/2022.01.12.22269023 doi: medRxiv preprint This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 13, 2022. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 13, 2022. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 13, 2022. ; https://doi.org/10.1101/2022.01.12.22269023 doi: medRxiv preprint for use under a CC0 license.

This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 13, 2022. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 13, 2022. ; https://doi.org/10.1101/2022.01.12.22269023 doi: medRxiv preprint

Convalescent COVID-19 plasma donors were prospectively enrolled onto an institutional review board-approved protocol (Clinical Trials Registration, NCT04360278) 19 and provided written informed consent for the study. Among them, 12 convalescent plasma donors with high titer neutralizing antibodies against SARS-CoV2 were selected and 20-40 ml of blood was collected from each of the 12 donors. Eligibility criteria included molecular or serologic laboratory evidence of past COVID-19 infection, and complete recovery from COVID-19, with no symptoms for ≥28 days or ≥14 days with a negative molecular test after recovery. PBMCs were prepared using density centrifugation on a Ficoll-Paque gradient. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 13, 2022. ; https://doi.org/10.1101/2022.01.12.22269023 doi: medRxiv preprint (Perkin Elmer, Waltham, MA, USA). Plasma was tested using two-fold serial dilutions from 1:40 to 1:1280 with four replicates per dilution. Results were calculated as the highest dilution of plasma leading to at least 50% reduction of SARS-CoV-2 titers. Each assay was controlled with internal addition of an S-specific neutralizing polyclonal antibodies. If a 1:40 dilution did not lead to at least 50% reduction of viral titer, results were reported as <1:40 even though some inhibition of virus propagation may have been present. To enable analysis of nAb kinetics over time, a value of 1:20 was used as a surrogate for results <1:40 since this value was the next serial 2-fold titer below the lowest positive result.

Total RNA was extracted from PBMCs using RNeasy mini kit (Qiagen) and 1 st strand cDNA was reverse transcribed with oligo(dT) as a primer with a kit from GE Healthcare and used as a template for antibody Fab coding fragment amplification. Briefly, the γ1 heavy chain Fd (variable and first constant region) was amplified with nine human heavy chain-specific 5′ primers and a human γ1-specific 3′ primer. The κ chain was amplified by PCR with seven human κ chain-specific 5′ primers and a 3′ primer matching the end of the constant region 40 . The λ chain was amplified by PCR with six human λ chain-specific 5′ primers and a 3′ primer matching the end of the constant region 41 . PCR was performed for 30 cycles at 95 °C for1 min, 52 °C for 1 min, and 72 °C for 1 min with AmpliTaq DNA polymerase (Applied Biosystems).

Amplified κ and λ chain DNA fragments were pooled, purified, digested with SacI and XbaI.

The restriction enzyme digested light chain fragments from one donor or pooled from 5 donors were then cloned into the pComb 3H vector by electroporation 42 This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 13, 2022. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 13, 2022. ; https://doi.org/10.1101/2022.01.12.22269023 doi: medRxiv preprint multiplicity of infection) by incubating at 37°C for 30 min without shaking, followed by 30 min at 120 rpm. Infected cells were harvested by centrifugation (5000 g for 5 min) and resuspended in 100 ml 2×TY supplemented with 100 μg/mL ampicillin and 50 μg/mL kanamycin. After overnight growth at 30°C at 250 rpm, the cells were removed by centrifugation (18000 g at 4°C for 20 min). The culture supernatant containing the phages was filtered through a 0.45-μm filter and then precipitated with 1/5 volume of 20% PEG8000 (polyethylene glycol) in a 2.5 M NaCl solution, for 1 h on ice. Phage particles were pelleted by centrifugation (9000 g at 4°C for 20 min) and re-dissolved in 1 mL 1×PBS.

The phage library was panned by affinity binding of Fab-expressing phages on S-2P coated on the wells of an ELISA plate. Blocking of plates and phages was conducted for 60 min using 3% skimmed milk in 1×PBS. All washing steps were performed using PBS containing 0.05% Tween20 (PBST). For each panning cycle, 1 μg/mL antigen was used to coat the polystyrene plate and after an overnight incubation, plates were washed and blocked. For the first panning cycle, approximately 1×10 11 phages were incubated with the antigen coated plates for 2 h, followed by a total of 20 washes with PBST. The eluted phages were amplified in E. coli Top 10 cells. Bacterial culture was plated on 2×TY-Amp-Glu agar and incubated overnight at 30°C.

Clones were harvested into 5 ml 2×TY-Amp-Glu and phage production for the next round of panning, which was conducted in 40 ml medium, as described above. Two additional panning cycles were repeated using the same protocol. Following three cycles of panning, the selected phages were used for infection of E. coli. Single colonies were randomly picked from the third cycle output and screening of specific binders was performed, using phage ELISA against S-2P, with a BSA coated-plate as a negative control.

We sequenced the heavy-chain variable region (VH-DH-JH genes) of the ELISA-positive SARS-CoV-2 S-2P-specific clones obtained from each library using the Applied BioSystems model 3730 automated DNA sequencer with a modified Sanger method. The closest human for use under a CC0 license.

This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 13, 2022. ; https://doi.org/10.1101/2022.01.12.22269023 doi: medRxiv preprint germline V(D)J gene segments for each unique sequence were determined using DNAPLOT with IMGT sequence database (http://www.imgt.org/IMGT). The framework and CDRs were assigned according to IMGT nomenclature. The somatic mutations were identified by comparison of V-genes (from framework 1 to 3) with the closest germline counterpart. The first 28 nucleotides corresponding to the primer sequence were not included in the analysis. The distribution of VH and JH gene usage and HCDR3 length of anti-HBc was analyzed.

The phagemid containing light chain and heavy chain was cleaved with NheI and SpeI and recircularized after removal of the phage gene III DNA fragment from the vector to encode soluble Fab. Bacteria containing circularized DNA without phage gene III were cultured in 2×TY medium containing 2% glucose, 100 µg/mL ampicillin, and 15 µg/mL tetracycline at 30°C until the OD600 reached 0.5-1. The culture was diluted 5-fold in 2×YT medium without glucose and containing 0.2 mM isopropyl β-D-thiogalactoside (IPTG), and culture was continued at 27°C for 20 h for expression of soluble Fab. Because the Fab was tagged at the C terminus with (His)6, the expressed proteins were affinity-purified on a nickel-charged column and were further purified through a cation-exchange SP column (Cytiva).

For IgG production, Expi293F™ cells (Thermo Fisher) were transiently transfected with plasmids carrying the antibody heavy chain and light chains. Cells were grown for six days at This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 13, 2022. ; https://doi.org/10.1101/2022.01.12.22269023 doi: medRxiv preprint

For conventional antigen-binding ELISA, 96-well plates were coated with 100 µl/well containing 1 µg/ml protein in 1×PBS (pH 7.4) and incubated at room temperature overnight.

Serial dilutions of soluble Fab, IgG, or phage were added to the wells, and plates were incubated for 2 h at room temperature. The plates were washed, and the secondary conjugated antibody For RBD-competition ELISA, 96-well plates were coated with 100 µl/well containing 1 µg/mL of recombinant S-2P trimer in 1×PBS (pH 7.4), and the plates were incubated at room temperature overnight. Each Fab was 3-fold serially diluted from a starting concentration of 3 µg/mL in 3% milk/PBS or in 3% milk/PBS containing recombinant RBD protein (Sino Biological #40592-V08B) at fixed concentration (5 µg/mL). Following incubation for 2 h at room temperature, the plate was washed, and a secondary anti-human Fab-HRP antibody (Jackson ImmunoResearch) was added for 1 h at room temperature. The plate was then washed, and the reaction was developed by adding tetramethylbenzidine substrate (KPL; Gaithersburg, MD). The reaction was stopped after 10 min by addition of sulfuric acid. The plates were read at OD450 in an ELISA plate reader. The data were plotted, and dose-response curves with and without inhibition with RBD were generated using Prism software (Graphpad Software, Inc., San Diego, CA).

For antibody cross-competition ELISA, 96-well ELISA plates were coated with 100 µl/well containing 1 µg/mL of recombinant S-2P trimer in 1×PBS (pH 7.4) and the plates were incubated at room temperature overnight. To test cross-competition among the mAbs, the IgG for use under a CC0 license. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 13, 2022. ; https://doi.org/10.1101/2022.01.12.22269023 doi: medRxiv preprint version of each mAb was incubated at 0.1 µg/ml with each of 11 Fabs at 1 µg/ml. An in houseproduced anti-poliovirus IgG antibody was used as a negative control 43 . Following incubation for 2 h at room temperature, the plates were washed, and a secondary anti-human IgG Fc-HRP antibody (Jackson ImmunoResearch) was added and incubated for 1 h at room temperature. The plates were then washed, and the reaction was developed by adding tetramethylbenzidine substrate (KPL; Gaithersburg, MD). The reaction was stopped after 10 min by addition of sulfuric acid. The plates were read at OD450 in an ELISA plate reader. The average value from three wells was used to calculate the percent competition using the following formula: [1-(average OD from wells containing test IgG with Fab -average OD from control wells)/(average OD from wells containing test IgG without Fab -average OD from control wells)] x100%.

The SPR experiments were performed on a Biacore™ T200 (Cytiva) at 25 °C in 10 mM HEPES Binding and kinetics studies were performed multiple times for each Fab. Increasing amounts of each Fab were injected over the surface at a flow rate of 30 µl/min with an association time of 120 sec and dissociation time of 180 sec, followed by a regeneration with 100mM CAPS, pH 11.5 for 90 sec. Binding data were analyzed using Biacore™ T200 Evaluation Software 3.1 (Biaeval) with fits to the Langmuir binding equation for a 1:1 interaction model. In addition, data were analyzed by surface site affinity distribution analysis by EVILFIT 44 . Values obtained with the two methods were consistent.

The SARS-Cov-2 pseudovirus neutralization assays were performed as previously reported 45 .

Briefly, single-round luciferase-expressing pseudoviruses were generated by co-transfection of for use under a CC0 license. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 13, 2022. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 13, 2022. ; https://doi.org/10.1101/2022.01.12.22269023 doi: medRxiv preprint Vero E6 cells by determination of the 50% tissue culture infectious dose (TCID50) as previously described 46 .

The mAbs were serially diluted in Opti-MEM and mixed with an equal volume of SARS-CoV-2 (100 TCID50) and then incubated at 37°C for 1 h. Mixtures were added to quadruplicate wells of Vero E6 cells in 96-well plates and incubated for four days. The 50% neutralizing dose (ND50) was defined as the highest dilution of serum that completely prevented cytopathic effect in 50% of the wells and was expressed as a log10 reciprocal value 47 This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 13, 2022. ; https://doi.org/10.1101/2022.01.12.22269023 doi: medRxiv preprint evaluated by limiting-dilution titrations on Vero E6 cells. The titration of SARS-CoV-2 was performed by determination of the TCID50 in Vero E6 cells and expressed as TCID50 per gram of tissue, as previously described 46 .

In the therapeutic study, 60 male Syrian hamsters, aged 9-10 weeks, were randomly divided into three groups of 10 animals each, bled for serology and inoculated intranasally with 4.5 log10 TCID50 of SARS-CoV-2 WA-1 or B.1.351 in 100 µL volumes per animal. Twenty-four hours later, the animals were inoculated intraperitoneally with 0.5 mL of NE12, NA8, or IgG1 control at 12 mg/kg, diluted to the concentration of 2.4 mg/mL in PBS. Body weights and clinical symptoms were monitored daily from day -4 before virus inoculation through day 11 after inoculation. On day 3 post-inoculation, five animals per group were necropsied; nasal turbinates and lungs were collected and processed as above. Virus titers were determined by limiting-dilution titrations on Vero E6 cells as described above.

Data sets were assessed for significance using one-way ANOVA with Tukey's multiple comparison test, or, if indicated, by non-parametric Kruskal-Wallis test with a Benjamini, Krieger and Yekutieli false-discovery test. Statistical comparisons of weight changes between treatment groups were performed using a repeated-measures mixed-effects model with Tukey's multiple-comparison test. Data were only considered significant at p < 0.05. Analyses were performed using Prism 9 (GraphPad Software).

SARS-CoV-2 S-6P spike at a concentration of 0.5 mg/ml in PBS was mixed with Fab NA8 or Fab NE12 using a Fab-to-RBD molar ratio of 1:1, and the complex was used for specimen preparation after a brief (5-10 min) incubation at 4°C. To prepare cryo-EM specimens, Quantifoil R 2/2 gold grids were glow-discharged using a PELCO easiGlow device (air pressure: 0.39 mBar, current: 20 mA, duration: 30 s) immediately before vitrification using an FEI for use under a CC0 license. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 13, 2022. ; https://doi.org/10.1101/2022.01.12.22269023 doi: medRxiv preprint Vitrobot Mark IV plunger. The Vitrobot chamber was kept at 4°C and 95% humidity, and the drop volume was 2.7 µl. Datasets were collected at the National CryoEM Facility (NCEF), National Cancer Institute, using a Thermo Scientific Titan Krios G3 electron microscope equipped with a K3 direct electron detector and Gatan Quantum GIF energy filter (slit width: 20 eV) (Extended Data Table 4 ).

Single particle analysis was performed using the Frederick Research Computing Environment (FRCE) computing cluster. MotionCorr2 was used for patch-based movie frame alignment 49 .

Contrast transfer function parameters were estimated with ctffind 4.1 50 . The following steps were performed using Relion 3.1.0 51 , unless otherwise stated. Particle picking was performed using the template-free Laplacian-Gaussian filter-based approach. Particles were first extracted with 4x binning and subjected to 2D and 3D classification, with the low-pass filtered cryo-EM map of individual SARS-CoV-2 S-2P spike at pH 7.4 serving as the initial 3D model. Particles contributing to high-quality 3D classes were then re-extracted with 2x binning, and the above procedure was repeated. Finally, the best particles were re-extracted without binning, and the 3D map was iteratively improved with rounds of 3D auto-refinement, CTF refinement, and Bayesian polishing. For local refinement, a soft mask encompassing one RBD in the down position with the bound Fab and the neighboring NTD was created after segmenting the refined ensemble map in UCSF Chimera 52 and used for auto-refinement with limited angular search (-sigma_ang = 5).

Resolution was calculated using the gold-standard approach 53 at the FSC curve threshold of 0.143. Local resolution was determined with ResMap 1.1.4 54 .

An RBD from the cryo-EM structure of the S-2P spike at pH 4.0 (PDB ID 6xlu) was docked into the locally refined cryo-EM map, along with an NTD from the same structure and a homology model of the corresponding Fab prepared using the SWISS-MODEL server 55 . The atomic model for use under a CC0 license. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 13, 2022. ; https://doi.org/10.1101/2022.01.12.22269023 doi: medRxiv preprint was refined by alternating rounds of model building in Coot 56 and real-space refinement in Phenix 57 . Structure validation was performed with Molprobity 58 . Map-model correlations were evaluated with phenix.mtriage 59 . Molecular graphics and analyses were performed with UCSF Chimera 60 .

Antigenic drift: Understanding COVID-19

Tackling COVID-19 with neutralizing monoclonal antibodies

Classification of Omicron (B.1.1.529) SARS-Cov-2 Variant of

The Johns Hopkins Coronavirus Resource Center Home Page

A pneumonia outbreak associated with a new coronavirus of probable bat origin

SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma

Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7

Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England

Data, disease and diplomacy: GISAID's innovative contribution to global health

Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. bioRxiv

Reduced neutralization of SARS-CoV-2 Omicron variant by vaccine sera and monoclonal antibodies

Booster of mRNA-1273 vaccine reduces SARS-CoV-2 Omicron escape from neutralizing antibodies. medRxiv

SARS-CoV-2 Omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for infection

Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses bioRxiv

Considerable escape of SARS-CoV-2 Omicron to antibody neutralization

Extremely potent human monoclonal antibodies from COVID-19 convalescent patients

Chimpanzee/human mAbs to vaccinia virus B5 protein neutralize vaccinia and smallpox viruses and protect mice against vaccinia virus

Role of humoral immunity against hepatitis B virus core antigen in the pathogenesis of acute liver failure

Naturally Acquired SARS-CoV-2 Immunity Persists for Up to 11

Months Following Infection

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Recognition of the SARS-CoV-2 receptor binding domain by neutralizing antibodies

Individual variation in the germline Ig gene repertoire inferred from variable region gene rearrangements

Expressed antibody repertoires in human cord blood cells: 454 sequencing and IMGT/HighV-QUEST analysis of germline gene usage, junctional diversity, and somatic mutations

A Therapeutic Non-self-reactive SARS-CoV-2 Antibody Protects from Lung Pathology in a COVID-19 Hamster Model

Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike

Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein

SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness

The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates

Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail

Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies

Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development

REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters

Structure-based design of prefusion-stabilized SARS-CoV-2 spikes

SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies

Structural basis of receptor recognition by SARS-CoV-2

The dual function monoclonal antibodies VIR-7831 and VIR-7832 demonstrate potent in vitro and in vivo activity against SARS-CoV-2

B.1.1.529 escapes the majority of SARS-CoV-2 neutralizing antibodies of diverse epitopes

a comprehensive database for human and mouse immunoglobulin and T cell receptor genes

Micro-Neutralization Assay for Assessment of SARS-CoV-2 (COVID-19) Virus-Neutralizing Antibodies in Human Clinical Samples

Simian immunodeficiency virus (SIV) envelope-specific Fabs with high-level homologous neutralizing activity: recovery from a long-term-nonprogressor SIV-infected macaque

Linkage of recognition and replication functions by assembling combinatorial antibody Fab libraries along phage surfaces

Assembly of combinatorial antibody libraries on phage surfaces: the gene III site

Chimpanzee-human monoclonal antibodies for treatment of chronic poliovirus excretors and emergency postexposure prophylaxis

Measuring Protein Interactions by Optical Biosensors

Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates

A single intranasal dose of a live-attenuated parainfluenza virus-vectored SARS-CoV-2 vaccine is protective in hamsters

A simple method of estimating fifty per cent endpoints

Prior infection and passive transfer of neutralizing antibody prevent replication of severe acute respiratory syndrome coronavirus in the respiratory tract of mice

MotionCor2: anisotropic correction of beam-induced motion for improved cryo-electron microscopy

CTFFIND4: Fast and accurate defocus estimation from electron micrographs

RELION: implementation of a Bayesian approach to cryo-EM structure determination

UCSF Chimera-a visualization system for exploratory research and analysis

Outcome of the first electron microscopy validation task force meeting

Quantifying the local resolution of cryo-EM density maps

SWISS-MODEL: homology modelling of protein structures and complexes

Coot: model-building tools for molecular graphics

Macromolecular structure determination using X-rays, neutrons and electrons: recent developments in Phenix

MOLPROBITY: structure validation and all-atom contact analysis for nucleic acids and their complexes

New tools for the analysis and validation of cryo-EM maps and atomic models

UCSF Chimera--a visualization system for exploratory research and analysis

A contributed to donor recruitment and blood sample collection. Z.C. generated Fab libraries and cloned monoclonal antibodies. H.N. and A.P. contributed to plasmid DNA preparation and tissue culture for IgG production. P.Z. and P.L. produced pseudoviruses and performed pseudovirus neutralization assays

generated and characterized the SARS-CoV-2 stocks for the animal studies. A.O. expressed, purified, and provided S-6P spike for cryo-EM structural analysis. T.S. carried out specimen preparation for cryo-EM experiments. Y.T. performed cryo-EM experiments and with P.D.K. performed data analysis and interpretation of the cryo-EM structures

We thank John R. Mascola, Kizzmekia S. Corbett, Nicole Doria-Rose, Lingshu Wang, Kevin 

The authors declare that they have no competing interests.

All data presented in this study are available within the article or from the corresponding authors upon request. Source data are provided with this paper. The antibody sequences reported in this paper have been deposited in the GenBank database (accession nos. OM179962-OM179997). The ensemble cryo-EM maps of the NE12/spike trimer and NA8/spike trimer complexes were deposited to the Electron Microscopy Data Bank (EMDB) with accession numbers EMD-XXXX and EMD-XXXX, respectively. The locally refined maps of the NE12/spike trimer and NA8/spike trimer complexes were deposited to EMDB with accession numbers EMD-